AArtificial intelligence Read More AI stocks rebound, and why J&J’s earnings guidance cut is not cause for concernJuly 30, 2026 Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
HHealthcare Read More Novo Nordisk looks to block Eli Lilly weight-loss drug adsJuly 29, 2026 The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters Novo Nordisk said on…
HHealthcare Read More FedEx is chasing the GLP-1 boom. Why healthcare logistics means big businessJuly 27, 2026 The boom in GLP-1 weight-loss drugs and other specialized medicines has created lucrative logistics opportunities in an industry…
MMedication Read More FDA is urged by advocacy group to ban DTC prescription drug adsJuly 23, 2026 Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
HHealthcare Read More Eli Lilly will file for approval of retatrutide obesity drug in 2027July 23, 2026 The Eli Lilly logo appears on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake…
MMedication Read More Barriers may keep Merck’s new cholesterol drug from successJuly 22, 2026 A long-awaited moment in preventive cardiology arrived last week, when enlicitide (which Merck is selling under the name…
HHealthcare Read More What to know about testosterone replacement therapyJuly 20, 2026 US Secretary of Defense Pete Hegseth speaks during a press briefing at the Pentagon in Washington, DC, on…
HHealthcare Read More Market for psychedelic drugs to treat mental health gets a buy signalJuly 19, 2026 Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
MMedication Read More Ozempic for cats? GLP-1 weight-loss drugs are coming for your fat petJuly 18, 2026 A beautiful, but over weight Maine Coon Cat gets measured around the belly by a vet. Ryersonclark |…
HHealthcare Read More Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsJuly 18, 2026 AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…
HHealth Read More Popular diabetes drugs do not alter the risk of developing a blinding eye conditionJuly 17, 2026 An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – a type of…
MMedication Read More Natasha never expected to become addicted to prescribed opioids while battling endometriosisJuly 17, 2026 Natasha Trajkovski was 21 when she was first prescribed opioids. After having a C-section, she was diagnosed with…